There are currently no randomized, controlled clinical trials examining the effects of BPC-157 in humans
Gaussian 16, Revision C01, Frisch MJ, Trucks GW, Schlegel HB, Scuseria GE, Robb MA, Cheeseman JR, Scalmani G, Barone V, Petersson GA, Nakatsuji H, Li X, Caricato M, Marenich AV, Bloino J, Janesko BG, Gomperts R, Mennucci B, Hratchian HP, Ortiz JV, Izmaylov AF, Sonnenberg JL, Williams-Young D, Ding F, Lipparini F, Egidi F, Goings J, Peng B, Petrone A, Henderson T, Ranasinghe D, Zakrzewski VG, Gao J, Rega N, Zheng G, Liang W, Hada M, Ehara M, Toyota K, Fukuda R, Hasegawa J, Ishida M, Nakajima T, Honda Y, Kitao O, Nakai H, Vreven T, Throssell K, Montgomery JA, Peralta J, Ogliaro JE, Bearpark F, Heyd MJ, Brothers JJ, Kudin EN, Staroverov KN, Keith VN, Kobayashi TA, Normand R, Raghavachari J, Rendell K, Burant AP, Iyengar JC, Tomasi SS, Cossi J, Millam M, Klene JM, Adamo M, Cammi C, Ochterski R, Martin JWRL, Morokuma K, Farkas O
Synergistic Potential of the BPC-157 + TB-500 Research Blend When combined, BPC-157 and TB-500 target complementary pathways in regenerative research: BPC-157 provides localized cytoprotection and growth factor modulation, while TB-500 drives systemic cell motility and vascularization
Trichotillomania is also associated with depression and anxiety (2)
It also exibits questionable behaviour in the presence of UV light and was the center of a debate between the non-profit group, EWG (whose intentions are no doubt good, but its credibility is often questioned by scientists) and a group of scientists and dermatologists lead by Steven Q
